Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 180

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 180
---
5,828 46%Total revenue 115,360 114,790 570 —%Cost of Revenue:Cost of product revenue 65,559 68,808 (3,249)(5%)Cost of service and other revenue 11,709 10,588 1,121 11%Amortization of acquired intangible assets4,711 7,172 (2,461)(34%)Loss on purchase commitment4,167 998 3,169 318%Total cost of revenue 86,146 87,566 (1,420)(2%)Gross profit29,214 27,224 1,990 7%Operating Expense:Research and development 74,428 107,456 (33,028)(31%)Sales, general and administrative 107,442 133,376 (25,934)(19%)Impairment charges15,000 93,200 (78,200)(84%)Amortization of acquired intangible assets363,708 13,377 350,331 2619%Change in fair value of contingent consideration(18,700)1,100 (19,800)(1800%)Total operating expense 541,878 348,509 193,369 55%Operating loss (512,664)(321,285)(191,379)60%Interest expense (5,214)(10,655)5,441 (51%)Other income, net 11,989 19,718 (7,729)(39%)Loss before income taxes(505,889)(312,222)(193,667)62%Income tax provision116 — 116 — Net loss$(506,005)$(312,222)$(193,783)62%

Q3 Fiscal 2025 Form 10-Q33

Revenue

Total Revenue

Total revenue increased $0.6 million during the nine months ended September 30, 2025 compared with the same period of 2024.Product revenue decreased $5.3 million, or 5%, primarily due to a decrease of $14.0 million, or 28%, in instrument revenue, partially offset by an increase of $8.7 million, or 17%, in consumable revenue.Service and other revenue increased $5.9 million, or 46%, primarily driven by an increase in Revio service contracts.

Instrument Revenue

Instrument revenue decreased during the nine months ended September 30